Genome Profiling, LLC

Genome Profiling, LLC is a Newark, Delaware-based biotechnology company that discovers and translates novel epigenetic biomarkers from next-generation sequencing data into precision assays for clinical applications. The organization utilizes proprietary analytics software to optimize this sequencing data for patient stratification, early disease detection, diagnostics, and treatment monitoring. Operating as a revenue-generating entity, the business maintains a workforce of five employees and generates approximately $500,000 in trailing twelve-month revenue. The company's core computational epigenetics technology originated from research conducted at the University of Delaware and was supported by funding from the National Science Foundation. The firm provides its biomarker discovery and analytics services directly to biopharma enterprises and clinical research institutions, including a notable clinical collaboration focused specifically on cerebral palsy research. Genome Profiling, LLC was co-founded in 2011 by Jeb Connor and Adam Marsh.

High-Level Overview

Genome Profiling, LLC (GenPro) is a biotechnology startup founded in June 2014 in Newark, DE, specializing in the discovery and commercialization of novel epigenetic biomarkers (EpiMarkers™) from next-generation sequencing (NGS) data.[1][2] The company develops high-throughput, low-cost precision qPCR assays for patient stratification, early disease detection, companion diagnostics, and insights into disease mechanisms, serving biopharma/biotech firms, clinical research institutions, clinicians, and patients.[1][2] With 5 employees and $500K in trailing twelve-month revenue, GenPro's GenPro Analytics™ platform uses genome-wide methylation profiling and machine learning to identify actionable EpiMarkers, offering superior sensitivity, specificity, and cost-effectiveness over genetic mutation-focused tools.[1][2] This addresses unmet needs in precision health by decoding the epigenome for phenotypic-driven insights beyond genomics.[2]

Origin Story

GenPro emerged in June 2014 as a bioinformatics-focused LLC, leveraging proprietary genome-wide methylation profiling to discover epigenetic biomarkers.[1][3][4] Key figures include Mort Goldman, who leads development of the GenPro Analytics™ platform, translating research into a secure, cloud-based system; Andrew, an experienced CFO overseeing finance across life sciences and other sectors; and founder Jeb Connor, driving AI and clinical trial applications in biopharma and biotech.[1][5] The idea stemmed from advancing Dr. Marsh's research innovations into scalable tools, filling gaps in NGS data analysis for epigenetic insights not captured by genomic biomarkers.[1][2] Early traction includes achieving $500K TTM revenue at the startup stage, with a focus on transforming NGS workflows for drug development and diagnostics.[1]

Core Differentiators

• Proprietary EpiMarker™ Discovery: Uses genome-wide DNA methylation profiling with machine learning in GenPro Analytics™ to identify novel epigenetic biomarkers for disease prediction, monitoring, and targeted assays—outperforming genetic variant tools in sensitivity and positive predictive value.[1][2][3]
• End-to-End Precision Workflow: Streamlines NGS from gDNA prep to qPCR or sequencing panels, reducing cost, time, and complexity while enabling phenotypic characterization, new drug targets, and patient-specific therapies.[2]
• Cloud-Based Scalability: Secure platform supports biopharma drug pipelines, clinical trials, and clinician diagnostics with actionable insights into genes, pathways, and epigenomic mechanisms.[1][2]
• Broad Applicability: Targets multiple diseases for stratification, early detection, and companion diagnostics, serving an underserved market beyond genomics.[1][2][4]

Role in the Broader Tech Landscape

GenPro rides the precision medicine and epigenetics wave, where epigenetic biomarkers provide dynamic phenotypic data complementing static genomic mutations, amid rising demand for personalized therapies and efficient clinical trials.[2][6] Timing aligns with NGS cost reductions and AI advancements in bioinformatics, enabling scalable epigenome decoding for biopharma to accelerate drug discovery and reduce trial failures.[1][2][5] Market forces like growing biotech investment in multi-omics and the shift to phenotypic-driven assays favor GenPro, influencing the ecosystem by "opening the door" to EpiMarker commercialization and new targets invisible to genomics alone.[2] As a player in consumer biotech, genomics, and clinical trials, it bridges research to clinical impact, enhancing precision health outcomes.[6]

Quick Take & Future Outlook

GenPro is poised for expansion by scaling GenPro Analytics™ partnerships with biopharma for trial optimization and diagnostics, potentially capturing more of the epigenetics market as multi-omics integrates into standard care. Trends like AI-enhanced biomarker discovery and qPCR adoption will propel growth, evolving its influence from niche innovator to key enabler in phenotypic precision health. With revenue momentum, expect funding rounds or acquisitions amplifying its role in decoding the epigenome for better patient outcomes—reinforcing its mission to accelerate precision health's promise.[1][2]